All KLD nasal sprays are formulated, filled, and tested in the United States under strict laboratory standards
Category 1 is part of an interim enforcement policy while FDA develops the formal list
Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2) Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions 1,5 Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis Medication interactions may occur with those on insulin, oral diabetes medications, oral contraceptives, and blood thinners
Data was acquired using Thermo Xcalibur 4.0 Software (Thermo Scientific, Waltham, MA USA) MS data processing and analysis were made using Skyline software (V20, MacCoss Lab, University of Washington, Seattle, WA)
Mechanistic themes seen in preclinical research In animal and mechanistic work, AOD-9604 has been associated with: Increased lipolysis (breaking down stored fat) Reduced lipogenesis (reducing fat storage) Interactions with -adrenergic pathways in adipose tissue have been discussed as part of its lipolytic signaling profile (OUP Academic) In obese animal models, AOD-9604 has shown reductions in body weight and body fat and changes consistent with increased fat mobilization
Oxidative stress may directly or indirectly stimulate the accumulation of extracellular matrix proteins